Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients. Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells.
Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients
Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells
PRINCETON, N.J., February 25, 2015--Bristol-Myers Squibb Company (NYSE:BMY) today announced data...
26 February 2015 | Bristol Myers Squibb press release
For more than three decades, scientists have tried unsuccessfully to develop an effective vaccine for HIV, the virus that causes AIDS. But now researchers say they have created an experimental drug that may function as a sort of "alternative" vaccine for the virus. The experimental drug, a protein known as eCD4-IG, blocks infection by keeping the virus from binding to the immune cells that are the virus's target. In tests on monkeys, the drug "candidate" proved to be extremely effective at blocking infection--even with the most virulent strains of HIV and its simian counterpart, SIV.
19 February 2015 | Huffington Post
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that it had concluded its Phase 2b treatment substitution study and reported 39 patients out of 40 participating in the study passed 4 weeks of monotherapy with PRO 140.
05 February 2015 | CytoDyn press release
New findings, published today by researchers at the University of California, San Diego School of Medicine, open the door to the development of new therapies to block or decrease cognitive decline due to HIV-associated neurocognitive disorders, estimated to affect 10 to 50 percent of aging HIV sufferers to some degree.
04 February 2015 | Medical Xpress
ABX464 inhibits the biogenesis of viral RNA required for the replication of the HIV virus, a mechanism of action never before explored. ABX464 could be administered less frequently and for shorter periods than current HIV treatments due to its long lasting impact on viral load
02 February 2015 | ABIVAX press release
Combined fixed-dose tablet of darunavir and cobicistat can help reduce number of pills in a combination antiretroviral treatment regimen.
30 January 2015 | Janssen press release
Evotaz is coformulated to be one pill, once-daily, combining the protease inhibitor atazanavir, which is marketed as Reyataz (atazanavir 200 mg/300 mg) capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences, Inc.
30 January 2015 | Bristol-Myers Squibb press release
On 22 January 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dutrebis, 150 mg lamivudine/300 mg raltegravir, film-coated tablet intended for the treatment of human immunodeficiency virus (HIV 1) infection in adults, adolescents, and children.
26 January 2015 | Street Insider
In general, the integrase ihibitors raltegravir and dolutegravir have potent anti-HIV activity and have relatively few interactions with other drugs. However in clinical trials of raltegravir, strains of HIV that can resist raltegravir have emerged in up to 60% of heavily treatment-experienced people, and up to 8% of participants who have never taken HIV drugs before. A study in France of patients who had virologial failure to HIV therapy while taking raltegravir has found that 61% had HIV that was still susceptible to all integrase inhibitors. In cases where HIV was resistant to raltegravir, 14% were also resistant to dolutegravir.
21 January 2015 | CATIE
The new anti-HIV integrase inhibitor dolutegravir is a highly potent drug. Alain Lafeuillade, a clinical researcher for 20 years in HIV disease, observed that Dolutegravir is highly effective alone in patients without integrase resistance. "Plasma viral load remained undetectable in my patients, and proviral HIV DNA in cells remained stable with only 50 mg 2 to 3 times a week," he said. He is proposing a low-dose dolutegravir monotherapy trial.
21 January 2015 | MMD Newswire